Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood protein predict metabolic changes after gastric bypass?

NCT ID NCT07774208

Knowledge-focused Sponsor: Istanbul University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study looks at how a protein called FABP4, which is linked to fat metabolism, changes in the blood after Roux-en-Y gastric bypass surgery. Researchers are following 28 adults who had the surgery, measuring FABP4 levels along with weight, body composition, inflammation, and gut hormones at 3 and 6 months. The goal is to see if different patterns of FABP4 change are related to the amount of weight loss or other metabolic improvements. This is an observational study, so it does not test a treatment but aims to better understand the body's response to surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study succeeds, it could help explain why some people have different metabolic responses after gastric bypass, potentially guiding more personalized follow-up care.
What could go wrong
This is a small, retrospective observational study, so it cannot prove cause and effect. The findings may not apply to everyone and need confirmation in larger, prospective studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

28 people

The number who actually took part.

Started

Apr 2013

Finished

Feb 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults undergoing Roux-en-Y gastric bypass (RYGB) performed by a single surgeon at Istanbul University, Istanbul Faculty of Medicine. The cohort comprised 16 patients previously enrolled in the control (probiotic-only) arm of a completed randomized trial (NCT03517345) and 12 additional consecutive patients undergoing RYGB by the same surgeon during a comparable period who were not enrolled in that trial. Patients using GLP-1 receptor agonists or insulin at any study time point were excluded.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults who underwent Roux-en-Y gastric bypass (RYGB), performed by a single surgeon * Completed baseline, 3-month, and 6-month clinical and anthropometric assessments Exclusion Criteria: * Use of GLP-1 receptor agonists at any study time point * Use of insulin at any study time point * Missing 6-month FABP4 measurement (excluded from FABP4-based longitudinal/group analyses; n=1)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bariatric surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Inflammation Insulin Resistance Obesity obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bariatric surgery Bariatric surgery (gastric bypass) Insulin resistance Obesity (bmi > 35) Obesity (bmi>30)

More trials for these conditions

Other studies related to the condition(s) this trial covers.